GAM
NAGE

Gemmer Asset Management’s Niagen Bioscience NAGE Stock Holding History

Gemmer Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$3K – 1545
2021
Q1 		$3K Sell
300
-300
-50% -$2.38K ﹤0.01% 1315
2020
Q4 		$3K Buy
+600
New +$2.92K ﹤0.01% 1276

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gemmer Asset Management's NAGE Position: Q2 2021 in Review

Gemmer Asset Management sold out of Niagen Bioscience (NAGE) in Q2 2021, closing a stake of 300 shares — an estimated $3K sold.

Gemmer Asset Management first reported a position in NAGE in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 101 funds tracked by Wall St. Rank hold NAGE as of Q2 2021.

  • Gemmer Asset Management reported no remaining Niagen Bioscience position as of Q2 2021 after selling out during the quarter.
  • Gemmer Asset Management sold 300 Niagen Bioscience shares in Q2 2021, an estimated $3K.
  • Gemmer Asset Management first reported a position in Niagen Bioscience in Q4 2020 and held it in 2 quarters.
  • Gemmer Asset Management's Niagen Bioscience position peaked at $3K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2021.

Based on Gemmer Asset Management's 13F filing for Q2 2021, filed 23 Jul 2021.